top of page

Our Collaborators

MSIN has been made possible in collaboration with the following:

MSIN is a multi-stakeholder collaborative and as such, leverages all partners who are part of the MS care continuum. While our focus, advisement, and part of our leadership oversight comes directly from people living with MS, our work is funded by generous supporters and key stakeholders in the MS care community, all of whom believe firmly in the importance of patient-driven care and using the power of implementation science to improve care. 

A note from Novartis

We believe that now is the time to invest and collaborate in the field of implementation science and research. In short, implementation science is the study of how we take therapies and clinical practices that we know are efficacious and create systems that allow for their routine use in clinical care. By better understanding how to remove barriers to care we hope to ensure that therapies reach the right patient at the right time to ensure the greatest clinical benefits regardless of practice setting or location. Novartis is deeply committed to this effort and therefore is collaborating with national patient advocacy organization the Multiple Sclerosis Association America (MSAA) and the implementation science research team at UTHealth Houston in the development of the MS Implementation Network (MSIN). This learning health system will be a leader in understanding the clinical practice of MS and will work to identify and implement practices leading to improved clinical outcomes for patients.



jason headshot_edited.jpg
Dharmesh headshot_edited.jpg

Jason W. Freeman, MD, MBA

Medical Director, Neuroscience and Ophthalmology

Novartis Pharmaceutical Corporation

Dharmesh Patel, MD

Vice President and Medical Team Head, Neuroscience & Ophthalmics

US Clinical Development & Medical Affairs

Novartis Pharmaceutical Corporation

bottom of page